Brenntag launches biopharma brand

Brenntag has launched Byphar, a specialised biopharma brand that combines all of its raw materials, advanced facilities and value added services in this field. It is designed, the firm said, “to bring quality, efficiency and flexibility to every stage of biopharmaceutical manufacturing”. 
 

The raw materials are organised into three defined categories, all of which will be available from July 2026 and which are tailored to specific risk levels and development stages:

• Byphar Explore: Non GMP materials for early phase development, R&D and non critical applications, monograph compliant where applicable, with essential regulatory documentation
• Byphar Enhance: GMP compliant materials suitable for all biopharmaceutical manufacturing stages, following IPEC and EXCiPACT guidelines and offering full regulatory ready documentation
• Byphar Excel: LBLE-critical raw materials for high risk applications, produced under GMP conditions, multi-compendial where applicable, and supported by extensive regulatory documentation
   

The brand integrates the products of several major partners of Brenntag, notably Budenheim’s high purity, Citribel high volume production of citric acid and citrates, K+S’s pharmaceutical grade salts from proprietary NaCl and KCl resources and Kerry cGMP acetates for critical applications. It is all engineered to support emerging biotechs, CDMOs and makers of vaccines, biosimilars and diagnostics using manufacturing processes, such as mAbs and ADCs, recombinant proteins, cell and gene therapies and nucleic acids.